• There are several reports providing evidences that functiona

  2024-09-10

  

  There are several reports providing evidences that functional and mechanistic connection between Sirt1 and LKB1/AMPK in metabolic regulation [26], [32], [33]. It has been reported that the deacetylation of LKB1 by Sirt1 is one of the determining factors of the subcellular localization of LKB1. In ag

• br Concluding Remarks and Future Perspectives The collective

  2024-09-10

  

  Concluding Remarks and Future Perspectives The collective evidence from studies detailing the functions of AMPK in the neuromuscular system, combined with those in DMD, SMA, and DM1 surveyed in the present review, strongly suggests that AMPK is a central mediator of neuromuscular determination, m

• br Acknowledgments The authors thank Claudia

  2024-09-10

  

  Acknowledgments The authors thank Claudia Wittrock for her excellent technical assistance. The work was supported by grants of the Deutsche Forschungsgemeinschaft (SFB974 TP B05) and of the Anton-Betz-Stiftung to N.K. A.M. is an associate member of the iBrain graduate school at the University of

• br Materials and methods br Results br Discussion Intracellu

  2024-09-10

  

  Materials and methods Results Discussion Intracellular metabolic pathways of sugar, such as glycolysis and TCA cycle, provide material and energy for the synthesis of other substances, including amino acids. Thus, the content of sugars and their metabolic pathways are important for amino Si

• Benzoylhypaconitine Aldose reductase ALR EC the first

  2024-09-10

  

  Aldose reductase (ALR2, EC1.1.1.21), the first enzyme in the polyol pathway, is a monomeric oxidoreductase that catalyses the NADPH-dependent reduction of a wide variety of carbonyl compounds, especially glucose. In this metabolism pathway, glucose is firstly reduced to sorbitol catalyzed by ALR2 wi

• In this study we demonstrated that DRR protein level

  2024-09-10

  

  In this study, we demonstrated that DRR1 protein level in GBM tissues was significantly higher compared to normal PLX7904 tissues. This data suggested that DRR1 might play a role in the tumorigenesis of glioma. To investigate whether DRR1 could accurately predict the outcome in patients with glioma

• Cancers that responded to immune checkpoint inhibitors were

  2024-09-10

  

  Cancers that responded to immune checkpoint inhibitors were shown to present a type I interferon (IFN) signature in the TME 33, 34. Type I IFNs positively regulate the expression of tumor antigens and their crosspresentation by DCs to tumoricidal CTLs. Furthermore, CD8+ T cell develops full effector

• br Hyperadiponectinemia in disease conditions Other evidence

  2024-09-09

  

  Hyperadiponectinemia in disease conditions Other evidence indicates that hyperadiponectinemia does not necessarily always imply a healthy outcome. Indeed, a recent study suggested that hyperadiponectinemia occurs in various diseases. Given that the risk for AD and vascular dementia is increased i

• Does dietary caffeine interfere with antinociception by othe

  2024-09-09

  

  (8) Does dietary caffeine interfere with antinociception by other modalities that alter pain (TENS, exercise, joint mobilization, water immersion therapy)? Caffeine and/or A1R antagonists inhibit antinociception by each of these modalities in preclinical studies, such that there is potential for int

• AdipoRon is an orally active synthetic small molecule that a

  2024-09-09

  

  AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r

• Because LTs are proved to mediate multiple biological and pa

  2024-09-09

  

  Because LTs are proved to mediate multiple biological and pathological responses in various disease states, the 5-LO biosynthetic pathway producing LTs from AA have been the target of drug discovery efforts for over two decades. As observed from literature, a pile of research efforts has been direct

• Physiology genetics and biochemistry of CYP A br Clinical

  2024-09-09

  

  Physiology, genetics, and PSP of CYP17A1 Clinical presentation and diagnosis Treatment Acknowledgements I thank Dr. Hwei-Ming Peng for assistance with preparing Fig. 3. This work was supported by grant R01GM086596 from the National Institutes of Health. Introduction Prostate cancer is

• What can we learn about the anticancer therapeutic efficacy

  2024-09-09

  

  What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito

• br Conclusion br Acknowledgement This study was supported by

  2024-09-09

  

  Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Stroke is the leading cause of disability and the fifth leading cause of death in the United States (Writing Group et al., 2016). On average, every 4 min a human dies of stroke (Lackland et al., 2

• Our results clearly demonstrate that inhibition

  2024-09-09

  

  Our results clearly demonstrate that inhibition of ATM pathway activation results in resistance to Vγ2Vδ2 T cell-mediated cell death. Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treatment would promote the cytotoxicity of resistant ovarian cancer cells. To our knowledge, this is the

16071 records 111/1072 page Previous Next First page 上5页 111112113114115 下5页 Last page